Novo Nordisk achieves primary objectives of ONWARDS 3 and 4 trials with once-weekly insulin icodec demonstrating superior reduction in HbA1c vs insulin degludec in ONWARDS 3
Bagsværd, Denmark, 29 July 2022 – Novo Nordisk today announced headline results from the ONWARDS…